[Fixed ratio combinations GLP-1RA and basal insulin: literature review]
- PMID: 38433545
- PMCID: PMC10926250
- DOI: 10.14341/probl13312
[Fixed ratio combinations GLP-1RA and basal insulin: literature review]
Abstract
The progressive nature of type 2 diabetes mellitus leads to the need for insulin therapy in a significant proportion of patients. Very often start of insulin therapy in type 2 diabetes mellitus (T2DM) is associated with weight gain and a significant increase of hypoglycemia's risk. However, innovative options, such as fixed ratio combinations of glucagon-like peptide 1 receptor agonists (GLP-1RA) and basal insulin, minimize weight gain and hypoglycemia risks and allow a greater proportion of patients to achieve individual glycemic control goals without compromising safety parameters. This review includes a description of the randomized clinical trials, as well as the results of real clinical practice of the use of two currently existing fixed ration combinations of GLP-1RA and basal insulin - iDegLira and iGlarLixi.
Прогрессирующее течение сахарного диабета 2 типа (СД2) приводит к необходимости назначения инсулинотерапии у значительной части больных. Как правило инсулинотерапия при СД2 сопровождается набором массы тела и существенным увеличением риска гипогликемий. Однако современные опции, такие как фиксированные комбинации агонистов рецепторов глюкагоноподобного пептида-1 (арГПП-1) и базального инсулина, позволяют минимизировать набор веса и риск гипогликемий, а также позволяют большей доле пациентов достигать индивидуальных целей гликемического контроля без ухудшения параметров безопасности. Данный обзор включает описание рандомизированных клинических исследований, а также результатов реальной клинической практики применения двух существующих на сегодняшний день фиксированных комбинаций арГПП-1 и базального инсулина — иДегЛира и иГларЛикси.
Similar articles
-
Fixed-Ratio Combinations of Basal Insulin and GLP-1RA in the Management of Type 2 Diabetes Mellitus: Highlights from the Literature.Endocr Metab Immune Disord Drug Targets. 2021;21(4):626-646. doi: 10.2174/1871530320666200705211224. Endocr Metab Immune Disord Drug Targets. 2021. PMID: 32628602 Review.
-
Rationale for, Initiation and Titration of the Basal Insulin/GLP-1RA Fixed-Ratio Combination Products, IDegLira and IGlarLixi, for the Management of Type 2 Diabetes.Diabetes Ther. 2017 Aug;8(4):739-752. doi: 10.1007/s13300-017-0287-y. Epub 2017 Jul 18. Diabetes Ther. 2017. PMID: 28721686 Free PMC article. Review.
-
Minimizing Hypoglycemia and Weight Gain with Intensive Glucose Control: Potential Benefits of a New Combination Therapy (IDegLira).Adv Ther. 2015 May;32(5):391-403. doi: 10.1007/s12325-015-0208-2. Epub 2015 May 12. Adv Ther. 2015. PMID: 25962992 Free PMC article.
-
Fixed-ratio combination therapy for type 2 diabetes: the top ten things you should know about insulin and glucagon-like peptide-1 receptor agonist combinations.Postgrad Med. 2018 May;130(4):375-380. doi: 10.1080/00325481.2018.1450058. Epub 2018 Mar 20. Postgrad Med. 2018. PMID: 29521173 Review.
-
Direct comparison two fixed-ratio combination glucagon-like peptide receptor agonist and basal insulin on glycemic and non glycemic parameters in type 2 diabetes.BMC Endocr Disord. 2023 Feb 1;23(1):28. doi: 10.1186/s12902-023-01282-w. BMC Endocr Disord. 2023. PMID: 36726134 Free PMC article.
References
-
- Kahn SE. The importance of b-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab. 2001;86:4047-4058. doi: https://doi.org/10.1210/jcem.86.9.7713 - DOI - PubMed
-
- Dedov I., Shestakova M., Mayorov A., Mokrysheva N., Andreeva E. , Bezlepkina O., Peterkova V., Artemova E., Bardiugov P., Beshlieva D., Bondarenko O., Burumkulova F., Vikulova O., Volevodz N., Galstyan G., Gomova I., Grigoryan O., Dzhemilova Z., Ibragimova L., Kalashnikov V., Kononenko I., Kuraeva T., Laptev D., Lipatov D., Melnikova O., Mikhina M., Michurova M., Motovilin O., Nikonova T., Rozhivanov R., Smirnova O., Starostina E., Surkova E., Sukhareva O., Tiselko A., Tokmakova A., Shamkhalova M., Shestakova E., Jarek-Martynowa I., Yaroslavceva M.. Standards of Specialized Diabetes Care / Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 11th Edition. Diabetes mellitus. 2024 Feb;26(2S):1–157. doi: 10.14341/dm13042. - DOI
-
- Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753-2786. doi: https://doi.org/10.2337/dci22-0034 - DOI - PMC - PubMed
-
- Mauricio Dídac, Meneghini Luigi, Seufert Jochen, Liao Laura, Wang Hongwei, Tong Liyue, Cali Anna, Stella Peter, Carita Paulo, Khunti Kamlesh. Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA. Diabetes, Obesity and Metabolism. 2017 Mar;19(8):1155–1164. doi: 10.1111/dom.12927. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical